TXMD
TherapeuticsMD, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$23M
5Y Perf.-96.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
TXMD vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1690.08T
5Y Perf.-59.3%
TXMD vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | TXMD | DBVT |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
| Market Cap | $23M | $1690.08T |
| Revenue (TTM) | $3M | $0.00 |
| Net Income (TTM) | $302K | $-168M |
| Gross Margin | 96.6% | — |
| Operating Margin | -97.1% | — |
| Total Debt | $7M | $22M |
| Cash & Equiv. | $5M | $194M |
TXMD vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
TXMD
DBVT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | 100 | 3.5 | -96.5% |
| DBV Technologies S.… (DBVT) | 100 | 40.7 | -59.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TXMD vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TXMD leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. DBV Technologies S.A. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
TXMD
TherapeuticsMD, Inc.
The Income Pick
TXMD carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 0.49
- Rev growth 35.3%, EPS growth 74.3%, 3Y rev CAGR -11.9%
- Lower volatility, beta 0.49, Low D/E 26.2%, current ratio 1.92x
Best for: income & stability and growth exposure
DBVT
DBV Technologies S.A.
The Long-Run Compounder
DBVT is the clearest fit if your priority is long-term compounding.
- -87.1% 10Y total return vs TXMD's -99.5%
- +100.5% vs TXMD's +41.4%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | TXMD | 35.3% revenue growth vs DBVT's -100.0% |
| Quality / Margins | TXMD | 10.8% margin vs DBVT's 0.3% |
| Stability / Safety | TXMD | Beta 0.49 vs DBVT's 1.26 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | DBVT | +100.5% vs TXMD's +41.4% |
| Efficiency (ROA) | TXMD | 0.8% ROA vs DBVT's -89.0% |
TXMD vs DBVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2023
Segment breakdown not available.
TXMD vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLTXMDLAGGINGDBVT
DBVTDBV Technologies S.A.
1leads
TXMDTherapeuticsMD, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs DBVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
TXMD1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
TXMD5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
DBVT5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
TXMD1/1
Income & Cash Flow (Last 12 Months)
TXMD leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
TXMD and DBVT operate at a comparable scale, with $3M and $0 in trailing revenue.
| Metric | TXMDTherapeuticsMD, I… | DBVTDBV Technologies … |
|---|---|---|
| RevenueTrailing 12 months | $3M | $0 |
| EBITDAEarnings before interest/tax | -$2M | -$112M |
| Net IncomeAfter-tax profit | $302,000 | -$168M |
| Free Cash FlowCash after capex | $2M | -$151M |
| Gross MarginGross profit ÷ Revenue | +96.6% | — |
| Operating MarginEBIT ÷ Revenue | -97.1% | — |
| Net MarginNet income ÷ Revenue | +10.8% | — |
| FCF MarginFCF ÷ Revenue | +74.0% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +43.3% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +118.9% | +91.5% |
TXMD leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — TXMD and DBVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | TXMDTherapeuticsMD, I… | DBVTDBV Technologies … |
|---|---|---|
| Market CapShares × price | $23M | $1690.08T |
| Enterprise ValueMkt cap + debt − cash | $25M | $1690.08T |
| Trailing P/EPrice ÷ TTM EPS | -10.42x | -0.75x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 13.01x | — |
| Price / BookPrice ÷ Book value/share | 0.83x | 0.65x |
| Price / FCFMarket cap ÷ FCF | 31.31x | — |
Evenly matched — TXMD and DBVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
TXMD leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
TXMD delivers a 1.1% return on equity — every $100 of shareholder capital generates $1 in annual profit, vs $-130 for DBVT. DBVT carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to TXMD's 0.26x. On the Piotroski fundamental quality scale (0–9), TXMD scores 6/9 vs DBVT's 4/9, reflecting solid financial health.
| Metric | TXMDTherapeuticsMD, I… | DBVTDBV Technologies … |
|---|---|---|
| ROE (TTM)Return on equity | +1.1% | -130.2% |
| ROA (TTM)Return on assets | +0.8% | -89.0% |
| ROICReturn on invested capital | -11.4% | — |
| ROCEReturn on capital employed | -13.6% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 |
| Debt / EquityFinancial leverage | 0.26x | 0.13x |
| Net DebtTotal debt minus cash | $2M | -$172M |
| Cash & Equiv.Liquid assets | $5M | $194M |
| Total DebtShort + long-term debt | $7M | $22M |
| Interest CoverageEBIT ÷ Interest expense | -194.43x | -189.82x |
TXMD leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
DBVT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DBVT five years ago would be worth $3,172 today (with dividends reinvested), compared to $377 for TXMD. Over the past 12 months, DBVT leads with a +100.5% total return vs TXMD's +41.4%. The 3-year compound annual growth rate (CAGR) favors DBVT at 5.7% vs TXMD's -20.1% — a key indicator of consistent wealth creation.
| Metric | TXMDTherapeuticsMD, I… | DBVTDBV Technologies … |
|---|---|---|
| YTD ReturnYear-to-date | +20.0% | +3.6% |
| 1-Year ReturnPast 12 months | +41.4% | +100.5% |
| 3-Year ReturnCumulative with dividends | -49.0% | +18.1% |
| 5-Year ReturnCumulative with dividends | -96.2% | -68.3% |
| 10-Year ReturnCumulative with dividends | -99.5% | -87.1% |
| CAGR (3Y)Annualised 3-year return | -20.1% | +5.7% |
DBVT leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — TXMD and DBVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
TXMD is the less volatile stock with a 0.49 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DBVT currently trades 75.3% from its 52-week high vs TXMD's 67.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | TXMDTherapeuticsMD, I… | DBVTDBV Technologies … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.49x | 1.26x |
| 52-Week HighHighest price in past year | $2.95 | $26.18 |
| 52-Week LowLowest price in past year | $0.98 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +67.1% | +75.3% |
| RSI (14)Momentum oscillator 0–100 | 41.9 | 47.4 |
| Avg Volume (50D)Average daily shares traded | 22K | 252K |
Evenly matched — TXMD and DBVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
TXMD leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
| Metric | TXMDTherapeuticsMD, I… | DBVTDBV Technologies … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $46.33 |
| # AnalystsCovering analysts | — | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
TXMD leads this category, winning 1 of 1 comparable metric.
Key Takeaway
TXMD leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). DBVT leads in 1 (Total Returns). 2 tied.
Best OverallTherapeuticsMD, Inc. (TXMD)Leads 3 of 6 categories
Loading custom metrics...
TXMD vs DBVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is TXMD or DBVT a better buy right now?
Analysts rate DBV Technologies S.
A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — TXMD or DBVT?
Over the past 5 years, DBV Technologies S.
A. (DBVT) delivered a total return of -68. 3%, compared to -96. 2% for TherapeuticsMD, Inc. (TXMD). Over 10 years, the gap is even starker: DBVT returned -87. 1% versus TXMD's -99. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — TXMD or DBVT?
By beta (market sensitivity over 5 years), TherapeuticsMD, Inc.
(TXMD) is the lower-risk stock at 0. 49β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 159% more volatile than TXMD relative to the S&P 500. On balance sheet safety, DBV Technologies S. A. (DBVT) carries a lower debt/equity ratio of 13% versus 26% for TherapeuticsMD, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — TXMD or DBVT?
On earnings-per-share growth, the picture is similar: TherapeuticsMD, Inc.
grew EPS 74. 3% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — TXMD or DBVT?
DBV Technologies S.
A. (DBVT) is the more profitable company, earning 0. 0% net margin versus -123. 9% for TherapeuticsMD, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DBVT leads at 0. 0% versus -270. 3% for TXMD. At the gross margin level — before operating expenses — TXMD leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — TXMD or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is TXMD or DBVT better for a retirement portfolio?
For long-horizon retirement investors, TherapeuticsMD, Inc.
(TXMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 49)). Both have compounded well over 10 years (TXMD: -99. 5%, DBVT: -87. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between TXMD and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: TXMD is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.